Sg Americas Securities, LLC Provention Bio, Inc. Transaction History

Sg Americas Securities, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 28, 2023	BUY	$6.7 - $24.21 $259,973 - $939,396	38,802 Added 374.75%	49,156 $1.19 Million
Q4 2022 Feb 02, 2023	BUY	$4.52 - $10.57 $46,800 - $109,441	10,354 New	10,354 $109,000
Q1 2022 Apr 29, 2022	SELL	$3.4 - $7.88 $47,566 - $110,241	-13,990 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$5.59 - $7.39 $831,954 - $1.1 Million	-148,829 Reduced 91.41%	13,990 $79,000
Q3 2021 Nov 01, 2021	BUY	$5.66 - $8.33 $194,545 - $286,318	34,372 Added 26.76%	162,819 $1.04 Million
Q2 2021 Aug 12, 2021	BUY	$6.71 - $11.04 $68,582 - $112,839	10,221 Added 8.65%	128,447 $1.08 Million
Q1 2021 May 13, 2021	BUY	$10.12 - $19.45 $979,393 - $1.88 Million	96,778 Added 451.22%	118,226 $1.24 Million
Q4 2020 Feb 04, 2021	SELL	$11.79 - $18.94 $1.59 Million - $2.55 Million	-134,869 Reduced 86.28%	21,448 $363,000
Q3 2020 Nov 09, 2020	BUY	$10.34 - $15.2 $1.02 Million - $1.5 Million	98,405 Added 169.92%	156,317 $2.01 Million
Q2 2020 Jul 20, 2020	BUY	$7.81 - $17.0 $452,292 - $984,504	57,912 New	57,912 $817,000
Q4 2019 Jan 28, 2020	SELL	$5.84 - $14.9 $237,588 - $606,176	-40,683 Closed	0 $0
Q3 2019 Nov 04, 2019	BUY	$6.83 - $13.0 $277,864 - $528,879	40,683 New	40,683 $278,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.